Cantor Fitzgerald Predicts ABOS FY2026 Earnings

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) – Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Acumen Pharmaceuticals in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will earn ($1.21) per share for the year. The consensus estimate for Acumen Pharmaceuticals’ current full-year earnings is ($1.56) per share.

ABOS has been the topic of several other research reports. HC Wainwright dropped their price target on Acumen Pharmaceuticals from $15.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, March 28th. UBS Group dropped their price target on Acumen Pharmaceuticals from $6.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, March 28th.

Acumen Pharmaceuticals Price Performance

NASDAQ ABOS opened at $1.14 on Wednesday. The stock has a market capitalization of $69.05 million, a P/E ratio of -0.83 and a beta of 0.05. Acumen Pharmaceuticals has a 1 year low of $0.86 and a 1 year high of $3.60. The business’s fifty day moving average is $1.05 and its two-hundred day moving average is $1.40. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.43 and a current ratio of 10.43.

Acumen Pharmaceuticals (NASDAQ:ABOS) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.08. During the same period in the prior year, the firm posted ($0.25) earnings per share.

Institutional Trading of Acumen Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ABOS. JPMorgan Chase & Co. raised its stake in Acumen Pharmaceuticals by 1,387.2% during the 4th quarter. JPMorgan Chase & Co. now owns 937,908 shares of the company’s stock valued at $1,613,000 after purchasing an additional 874,842 shares during the period. Jane Street Group LLC raised its stake in Acumen Pharmaceuticals by 116.1% during the 4th quarter. Jane Street Group LLC now owns 30,740 shares of the company’s stock valued at $53,000 after purchasing an additional 221,144 shares during the period. Invesco Ltd. raised its stake in Acumen Pharmaceuticals by 544.1% during the 1st quarter. Invesco Ltd. now owns 127,798 shares of the company’s stock valued at $141,000 after purchasing an additional 107,956 shares during the period. ADAR1 Capital Management LLC acquired a new stake in Acumen Pharmaceuticals during the 4th quarter valued at $162,000. Finally, Deutsche Bank AG raised its stake in Acumen Pharmaceuticals by 468.7% during the 4th quarter. Deutsche Bank AG now owns 96,995 shares of the company’s stock valued at $167,000 after purchasing an additional 79,940 shares during the period. 71.01% of the stock is owned by institutional investors and hedge funds.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.